tbuckley/cabot-search huggingface dataset:
THU0282 Frequency of Adverse Events in Patients Treated with Infliximab in Rheumatology
Authors: F. Daoued, T. Angoulvant, S. Mammou, G. Paintaud, P. Goupille, D. Mulleman
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Data on safety in patients exposed to biologic therapies are mainly focused on rheumatoid arthritis (RA). Little is known about the infliximab safety profile in spondyloarthritis (SA). <h3>Objectives</h3> The aim of this study was to evaluate the clinical safety of infliximab in everyday practice. We assessed the incidence of adverse events requiring hospitalization, outpatient treatment or therapeutic modifications (stopping or postponing the treatment) in patients with rheumatic diseases (RA and SA). Then we tried to identify risk factors for adverse events. <h3>Methods</h3> Retrospective cohort study including the patients treated with infliximab between December, 2005 and January, 2012. We listed all the adverse events, which required an ambulatory treatment or a modification of the treatment with infliximab or a hospitalization. Then, patients with and without adverse events were compared. <h3>Results</h3> Two hundred and six patients received 2911 infusions during the period studied. We collected 224 infections with an incidence of serious infection of 5.3 cases for 100 patients/year, 22 skin reactions, 16 gastrointestinal events, 7 neuropsychiatric events and 9 neoplastic events. We did not identify risk factors for this first group of adverse events. We also collected 12 cardiovascular events occurring more frequently in hypertensive patient (p=0,005) and 26 immediate infusion reactions were more frequent in patients developing antibodies toward infliximab (p&lt;0.01), receiving a low dose of infliximab (p=0.01) and with a history of allergy (p=0.01). <h3>Conclusions</h3> Adverse events are frequent in patients treated with infliximab with mainly infectious events and infusion reaction events. This work underlines the importance of a clinical follow-up of the patients treated with infliximab and more particularly by anti-TNFα. <h3>Acknowledgements</h3> The authors thank Frederic Médina, Sophia Leclerc, Sophie-Anne Fauconnier and Alexis Lhommas for their cooperation for the collection of data and David Ternant for his help in data analysis and his advice for the development of this work.The authors thank Professor Bernard to have reviewed this work.Thanks to the medical and paramedical staff of Department of Rheumatology, pharmaco-toxicology laboratory and hospital pharmacy. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2695
A DEDICATED ATRIAL FIBRILLATION PROGRAM IMPROVES CATHETER ABLATION OUTCOMES AND ELECTROPHYSIOLOGY LAB RESOURCE UTILIZATION
Authors: Donna M. Suter, Kevin Floyd, Lawrence Rosenthal, Clifford Browning, Cynthia Ennis, J. Kevin Donahue, John Keaney, Theo Meyer, David McManus
Journal: Journal of the American College of Cardiology (2016)
SP0035 Raynaud’s phenomenon and systemic sclerosis: An update
Authors: Y. Allanore
Journal: Annals of the Rheumatic Diseases (2013)

Systemic sclerosis (SSc) is a multisystem auto-immune disease. The two main subtypes of SSc (limited and diffuse cutaneous subsets) typically have differing courses and prognoses. However, new classification criteria are under preparation and should allow to better identify SSc in the earliest stages, before skin involvement. In this line, there a renewed interest for Raynaud's phenomenon as an early symptom, and combined with anti-nuclear antibody or capillaroscopy testing, this may drive toward a window of opportunity for actively fighting against the progression of the disease. Recent work in SSc and related fibrotic diseases have identified several areas in which innate immunity can stimulate inflammation as well as fibrosis. This has been supported by several in vitro and in vivo data together with many genetic studies. Concomitantly, several lines of evidence have shown that epigenetic modifications contribute to the massive production of extracellular matrix proteins by skin fibroblasts. Proper categorization of SSc patients for research studies by use of new biomarkers potentially derived from these better understandings is critical, as disease heterogeneity may explain some of the inconsistencies of prior studies. Indeed, randomised controlled study mostly performed in patients with early diffuse cutaneous SSc have provided so far disappointing results. Some methodological limitations have been pointed out recently through meta-analysis and outcome measures need to be improved for assessing the fibrotic process. More consistent data have been reported for the vascular component of SSc with common vasodilators, such as calcium channel blockers and angiotensin converting enzyme inhibitors, and more potent drugs such as prostanoids, endothelin antagonists and phosphodiesterase V inhibitors. The most recent data obtained with these drugs will be presented and discussed together the preliminary experiences of the use of biologics in SSc. <h3>Disclosure of Interest</h3> Y. Allanore Grant/Research support from: Actelion, Pfizer, Roche
Endoscopic Ultrasound (EUS)-Guided Angiography: A Novel Approach to Diagnostic and Therapeutic Intravascular Interventions
Authors: P Magno, S Giday, J Buscaglia, CW Ko, L Wroblewski, MI Canto, AN Kalloo, SV Kantsevoy, SB Jagannath
Journal: Endoscopy (2006)

The ability to visualize and perform therapeutic intervention in the vascular tree makes interventional angiography an invaluable asset in patient care. Current non-surgical vascular interventions are performed via a percutaneous route. Aim: To assess the feasibility of EUS-guided angiography in a porcine model. Methods: This study was approved by the Animal Institutional Review Board. All procedures were performed on 50-kg pigs under general anesthesia with a linear echoendoscope (Olympus® GF-UCT140). The thoracic and abdominal aorta, celiac axis, superior mesenteric artery, splenic vein, portal vein, splenic artery, and hepatic veins were identified. Under the EUS and fluoroscopy guidance intravascular injection of iohexol contrast at a rate of 1 mL/second via 19, 22 and 25 gauge (g) fine-needle aspiration needles was done. Then the animals were eutanized for necropsy. Results: There was excellent EUS visualization of all major abdominal and mediastinal vessels. Selective vessel injections were performed without technical difficulties or acute hemodynamic compromise and demonstrated clear vascular opacification with a blush of the contrast. At necropsy, the 25-g needle did not cause any visible vascular damage or bleeding. The 22-g needle created a visible puncture site on the vessel without any active bleeding. The 19-g needle caused a localized vascular hematoma around large caliber vessels, and 150 mL of intra-abdominal blood. Injection of the contrast was technically easiest with the 19-gauge needle, and the most difficult with the 25-g needle. Conclusions: This is the first study to demonstrate the feasibility and technical challenges of EUS-guided angiography. Vascular injection using a 25-g needle can be performed safely but technical challenges remain to achieve a sufficient flow rate of contrast for adequate visualization of large vessels.
S98 A Novel Human Model To Study Alveolar Injury And Repair
Authors: J. Alcada, J. Ng-Blichfeldt, A. Proudfoot, M. Griffiths, C. Dean, M. Hind
Journal: Thorax (2014)

<h3>Introduction</h3> The development of regenerative therapies holds promise for the future treatment of parenchymal lung diseases. However, encouraging preclinical data from animal models have translated poorly in clinical trials. The cellular and molecular response to lung injury is difficult to study in man. To address this fundamental question, we have developed a novel <i>in vitro</i> human model. Precision cut lung slice (PCLS) culture is a well-established tool in airway biology and pharmacology. Here, we demonstrate lung parenchyma can be maintained and manipulated<i>in vitro</i> generating a tractable model, which allows study of lung injury and repair in man. <h3>Methods</h3> PCLS (500 µm) were generated from agarose-inflated lung lobes from human lungs maintained <i>ex-vivo</i> by perfusion and ventilation (EVLP). The slices were cultured in serum-free medium in a rotating incubator (37ºC, 5% CO<sub>2</sub>) and analysed at days 1, 3 and 7. Cell specific immunofluorescence markers were used to identify smooth muscle, type I and type II alveolar epithelial cells (AT1, AT2), vascular endothelial cells and proliferating cells (using αSMA, Aquaporin5, ProSPC, PECAM1 and Phospho-histone H3 respectively). Slice viability was confirmed using MitoTracker, LDH and Live/Dead assays. <h3>Results</h3> All of the expected cell types were identified in PCLS by immunofluorescence demonstrating that human PCLS maintained cellular differentiation in culture. Pro-SPC was predominant in the alveolar wall cells, particularly in the alveolar septal junctions, corresponding to known location of AT2 cells; AQ5 was distributed in thin bands lining the alveolar walls suggestive of the apical membrane of AT1 cells; αSMA was positive around airways, the known location of smooth muscle cells (SMCs); PECAM-1 was positive within alveolar walls corresponding to microvascular capillaries within alveolar septae. There was no significant cell proliferation during culture under basal conditions. Finally, cell viability studies demonstrated that PCLS can be maintained for up to 1 week in serum-free culture. <h3>Conclusion</h3> PCLS of human lung parenchyma remain differentiated and viable for up to 7 days in serum-free culture. In future, human PCLS derived from normal and injured regions of lung from the EVLP model may provide a novel means of studying alveolar repair in human lung <i>in vitro</i>.
Abstract 1256: Humoral autoimmune response to a RNA-binding protein HCC1/CAPER in hepatocellular carcinoma (HCC).
Authors: Liping Dai, Pengfei Ren, Xinxin Liu, Rosalia Ortega, Wu Yao, Kaijuan Wang, Mingan Wang, Eng M. Tan, Jianying Zhang
Journal: Cancer Research (2013)

Abstract HCC1 was originally cloned as a cell nuclear autoantigen in a patient with liver cirrhosis that progressed to HCC. The full-length sequence of HCC1encodes a protein of 530 amino acids and migrating at 64 kDa in SDS-PAGE. HCC1 has two isoforms of HCC1.4 and HCC1.3. The difference is that HCC1.3 has 6-amino acid deletion located in the RNP-1-like region of the putative third RNP-CS domain. The nucleotides and protein sequences of HCC1 were not found at that time in searching available databases and, therefore, it was considered as a novel gene with unknown function. Several years later, a group showed that HCC1 was a co-activator of activating protein-1 and estrogen receptors and proposed naming it CAPER. Further study by other group has demonstrated that HCC1/CAPER is a novel transcriptional co-activator for v-Rel that strongly suppresses its transforming activity, uncovering a tumor suppressor role for HCC1/CAPER in regulating Rel's oncogenic activity. Our previous studies have demonstrated that autoantibodies against tumor-associated antigens (TAAs) can be regarded as serological biomarkers in cancer immunodiagnosis. Whether autoantibodies to HCC1/CAPER can be also used as one of the markers in HCC remains to be investigated. In the present study, autoantibody responses to HCC1.3 and HCC1.4 were firstly evaluated by ELISA, western blotting and indirect immunofluorescence assay in sera from patients with HCC, liver cirrhosis and chronic hepatitis, as well as from normal human individuals. Immunohistochemistry (IHC) with HCC tissue array slides was also performed to analyze protein expression profiles of HCC1. The prevalence of anti-HCC1.4 antibodies was 13.5% (23/171) in HCC, which was significantly higher than that in normal human sera (1.1%). Whereas the significant difference regarding frequency of anti-HCC1.3 antibodies between HCC patients and normal individuals was not found. The frequency of HCC1 expression in HCC tissues was also significantly higher than that in normal liver tissues (57.5% vs. 0%; P&amp;lt;0.001). The data suggests that anti-HCC1.4 autoantibody may be a potential biomarker for HCC, but not HCC1.3. Further functional study of HCC1 may provide more evidence to address the question why these two isoforms of HCC1 can induce different humoral immune response in HCC patients. Citation Format: Liping Dai, Pengfei Ren, Xinxin Liu, Rosalia Ortega, Wu Yao, Kaijuan Wang, Mingan Wang, Eng M. Tan, Jianying Zhang. Humoral autoimmune response to a RNA-binding protein HCC1/CAPER in hepatocellular carcinoma (HCC). [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1256. doi:10.1158/1538-7445.AM2013-1256
Abstract 1085: MYC inhibition is a potent therapy against glioma and induces mitotic crisis in cancer cells.
Authors: Daniela Annibali, Jonathan R. Whitfield, Emilia Favuzzi, Toni Jauset, Erika serrano, Gerard Folch, Marta I. Cuartas, Alba Gonzalez, Lamorna Brown Swigart, Sergio Nasi, Gerard I. Evan, Joan Seoane, Laura Soucek
Journal: Cancer Research (2013)

Abstract Gliomas are the most common primary tumors affecting the adult human Central Nervous System (CNS). The most lethal is grade IV glioblastoma (GBM), which gives a median survival of only 15 months, but less severe grades also respond poorly to standard therapy. Myc is a bHLHZip transcription factor, causally implicated in most human tumors. In the past, we employed a dominant negative of Myc transactivation activity, termed Omomyc, and we showed that Myc inhibition is a potent strategy in cancer therapy, both in K-RasG12D-driven lung tumors and in T antigen-driven pancreatic β-cell insulinomas. Now, we make use of a mouse model of Ha-Ras driven glioma coupled with our Omomyc switchable model in order to assess Myc inhibition as a therapeutic strategy in glioma. Myc inhibition has a dramatic therapeutic impact in the animals, being able to both prevent formation and cause regression of tumors. We also tested neuroprogenitor cells derived from the same animal model as putative cells of origin of glioma. In this context, Myc inhibition reduced proliferation, increased death and impaired the self-renewal of Ha-Ras transformed neuroprogenitors. Similar results were obtained with human glioblastoma cell lines, which presented severe mitotic catastrophe as a consequence of Omomyc expression, revealing a new Achilles’ heel of glioblastoma. Finally, Myc inhibition was tested in orthotopic xenografts using patient-derived tumor samples and showed once again dramatic therapeutic impact, conferring a significant survival advantage to recipient animals. Conclusion: Myc inhibition is a potent therapeutic strategy in glioma and its effects include induction of mitotic crisis in tumor cells. Citation Format: Daniela Annibali, Jonathan R. Whitfield, Emilia Favuzzi, Toni Jauset, Erika serrano, Gerard Folch, Marta I. Cuartas, Alba Gonzalez, Lamorna Brown Swigart, Sergio Nasi, Gerard I. Evan, Joan Seoane, Laura Soucek. MYC inhibition is a potent therapy against glioma and induces mitotic crisis in cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1085. doi:10.1158/1538-7445.AM2013-1085
Disabling Positional Vertigo
Authors: Peter J. Jannetta, Margareta B. Møller, Aage R. Møller
Journal: New England Journal of Medicine (1984)

We have identified a group of patients with vestibular disorders whose symptoms are not consistent with the commonly recognized syndromes such as Meniere's disease, benign paroxysmal positional vertigo, and vestibular neuronitis. These patients have a constant positional vertigo and are often nauseated to an extent that makes them disabled. Their symptoms do not respond to conventional medical treatment or habituating therapy. We have found specific clinical-pathological signs in these patients that indicate that the vestibular nerve is compressed intracranially by blood vessels. Treatment of nine such patients by microvascular decompression of the eighth nerve brought total relief of symptoms in eight patients and improvement in one. We suggest that this syndrome be named disabling positional vertigo.
Work Activity of Longshoremen as Related to Death from Coronary Heart Disease and Stroke
Authors: Ralph S. Paffenbarger, Mary Elizabeth Laughlin, Alfred S. Gima, Rebecca A. Black
Journal: New England Journal of Medicine (1970)

In a 16-year follow-up study after multiphasic screening, 291 of 3263 longshoremen died of coronary disease, and 67 of stroke. Men with more sedentary jobs expended 925 fewer calories per work day and sustained coronary death rates one third higher than those among cargo handlers. Rate differences were largest at youngest ages and decreased steadily thereafter. Yet heavier cigarette smoking and higher systolic blood pressure had stronger influences in coronary mortality than sedentary work activity or heavier weight for height. Cargo handlers sustained death rates from stroke similar to those of more sedentary longshoremen. Mortality from stroke, however, was three times higher among men with higher levels of systolic blood pressure than among those with lower levels. Physical activity thus may have a more striking influence on myocardial infarction than on atherosclerosis.
ELECTROPHYSIOLOGICAL IMPLICATIONS OF LEFT ATRIAL WALL THICKNESS RELATED TO COMPLEX FRACTIONATED ELECTROGRAM, VOLTAGE AND CYCLE LENGTH
Authors: Junbeom Park, Chul Hwan Park, Jin-Kyu Park, Jae-Sun Uhm, Hui-Nam Pak, Moon-Houng Lee, Boyoung Joung
Journal: Journal of the American College of Cardiology (2015)
AB0984 Detailed Analysis of MRI Lesions in Subjects with ACPA but NO Clinical Signs of Arthritis
Authors: A. Kleyer, M. Krieter, F. Faustini, N. Kämmerer, J. Rech, G. Schett
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Autoimmunity develops long before the development of clinically signs of inflammation in patients with rheumatoid arthritis (RA). In this context the appearance of autoantibodies against citrullinated proteins (ACPA) may be an important step promoting the transition from autoimmunity to inflammatory disease. <h3>Objectives</h3> We hypothesized that healthy ACPA-positive individuals with no clinical signs of arthritis show subclinical soft tissue inflammation in their joints, which can be detected by magnetic resonance imaging (MRI). <h3>Methods</h3> Twelve ACPA positive healthy individuals without clinical signs of arthritis and normal acute phase reactant levels received an MRI (Siemens 1,5 Tesla Aera) examination of the dominant hand. Patients were taken from a cohort of ACPA-positive healthy individuals established at the University of Erlangen-Nuremberg. T1- and T2-weigthed MRI sequences were scored for synovitis, osteitis and bone erosions according to the OMERACT rheumatoid arthritis MRI scoring system (RAMRIS) by two independent assessors. Furthermore, the presence or absence of tenosynovitis was recorded. <h3>Results</h3> Data of twelve ACPA positive individuals [10 females (average age 49,8), 2 males (age: 54/39)] were analyzed. Mean level of CCP-antibodies were 251,7 U/ml (cut off: 10 U/ml), mean level for MCV–antibodies were 335 U/ml (cut off: 20 U/ml). Six subjects were also positive for rheumatoid factor (RF) with a mean level of 65,9 IE/ml (cut off 20 IE/ml). Synovitis (not higher than grade 1 in OMERACT Score) was seen in 7/12 subjects affecting 13% (11/84) of all assessed joints. Due to low-grade synovitis inter-reader reliability was low (κ-coefficient 0,53). Osteitis was detected in 3/12 subjects, involving 2,1% (6/276) of the evaluated bones. Osteitis was exclusively found in the carpal bones when present. Inter-reader reliability was high (κ-coefficient 1,00). Tenosynovitis of the extensor and/or flexor tendons was rather frequent and found in 7/12 subjects. Small bone erosions were seen in 9/12 subjects affecting 5,8% (16/276) of the bone surface. 75% of erosions did affect the carpal bones. <h3>Conclusions</h3> A subset of healthy ACPA-positive individuals, which are at risk for developing RA, show distinct inflammatory lesions in the MRI. The carpal joints are the preferentially affected anatomical region, whereas the MCP joints are rarely and the PIP joints never affected. Tenosynovitis was frequently present support the concept that inflammatory lesions in RA start in the tendons around the wrist. <h3>Acknowledgements</h3> <sup>*</sup>AK and MK contributed equally to this work <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3437
Case 5-2014
Authors: Meridale V. Baggett, Sarah E. Turbett, Shmuel S. Schwartzenberg, James R. Stone
Journal: New England Journal of Medicine (2014)

A 59-year-old man was admitted to this hospital because of fever, confusion, rash, thrombocytopenia, and renal failure, 10 days after a hunting trip in the Nevada valley. Diagnostic procedures were performed, and diagnostic test results were received from another hospital.
HOSPITAL VOLUME AND OUTCOMES IN PERIPHERAL VASCULAR INTERVENTIONS IN THE UNITED STATES
Authors: Sidakpal Panaich, Shilpkumar Arora, Nilay Patel, Nileshkumar Patel, Sopan Lahewala, Vikas Singh, Samir Patel, Ankit Chothani, Sohilkumar Manvar, Jay Patel, Ghanshyambhai Savani, Vinaykumar Panchal, Sadip Pant, Sunny Jhamnani, Abhishek Deshmukh, Apurva Badheka
Journal: Journal of the American College of Cardiology (2015)
Dépistage du carcinome épidermoïde de l'œsophage par chromoendoscopie au lugol chez des patients avec carcinome épidermoïde ORL: expérience monocentrique chez 424 patients
Authors: K Stroeymeyt, M Wangermez, A Michaud-Herbst, C Allières, D Tougeron, D Thomas, F Charier, X Dufour, P Beau, C Chagneau Derrode, M Beauchant, C Silvain, T Barrioz
Journal: Endoscopy (2011)

Introduction: Le but de notre travail a été d'évaluer la faisabilité en pratique quotidienne et la rentabilité du dépistage du carcinome épidermoïde de l'œsophage par chromoendoscopie au lugol lors du bilan initial du cancer ORL.